论文部分内容阅读
目的:观察复方甘草酸苷联合川芎嗪治疗酒精性肝病的疗效。方法:将160例酒精性肝病患者随机分为对照组、复方甘草酸苷组、川芎嗪组及联合治疗组,治疗4周后观察肝功能、肝纤维化指标、转化生长因子β1(TGFβ1)、白细胞介素-6(IL-6)、瘦素(Leptin)及肿瘤坏死因子-α(TNF-α)。结果:各组治疗后肝功能较治疗前均显著好转,肝纤维化指标、TGFβ1、IL-6、Leptin及TNF-α较治疗前均显著下降(P<0.05),对照组、复方甘草酸苷组及川芎嗪组之间治疗后肝功能、肝纤维化指标、TGFβ1、IL-6、Leptin及TNF-α无显著性差异(P>0.05),联合治疗组治疗后肝功能较对照组、复方甘草酸苷组及川芎嗪组显著改善(P<0.05),肝纤维化指标、TGFβ1、IL-6、Leptin及TNF-α较对照组、复方甘草酸苷组及川芎嗪组显著下降(P<0.05)。结论:复方甘草酸苷联合川芎嗪治疗酒精性肝病有效。
Objective: To observe the curative effect of compound glycyrrhizin and ligustrazine on alcoholic liver disease. Methods: 160 patients with alcoholic liver disease were randomly divided into control group, compound glycyrrhizin group, ligustrazine group and combination therapy group. After 4 weeks of treatment, liver function, hepatic fibrosis index, transforming growth factor β1 (TGFβ1) Interleukin-6 (IL-6), Leptin and tumor necrosis factor-α (TNF-α). Results: The liver function of all groups were significantly improved after treatment. The indexes of hepatic fibrosis, TGFβ1, IL-6, Leptin and TNF-α were significantly lower than those before treatment (P <0.05). The levels of compound glycyrrhizin There was no significant difference in liver function, liver fibrosis index, TGFβ1, IL-6, Leptin and TNF-α between the two groups after treatment (P> 0.05) Glycyrrhizin group and ligustrazine group were significantly improved (P <0.05), liver fibrosis index, TGFβ1, IL-6, Leptin and TNF-αwere significantly decreased compared with the control group, compound glycyrrhizin group and ligustrazine group (P < 0.05). Conclusion: Compound glycyrrhizin and ligustrazine are effective in treating alcoholic liver disease.